Sofiva Genomics Co.,Ltd.
6615
Rank in Stocks
#26237
Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan,... Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan, offers a comprehensive range of genetic testing services to both domestic and international clients. The company's diverse diagnostic solutions are designed to support expectant parents, individuals with inherited conditions, and their families. Their extensive prenatal diagnostics include screenings for conditions such as thalassemia carrier status, various microdeletion syndromes, single-gene abnormalities, common chromosomal anomalies, and specific skeletal dysplasia mutations. They also provide multi-gene panel testing for inherited diseases, folate metabolism genetic analysis, carrier screening for spinal muscular atrophy (SMA) and Fragile X syndrome, congenital infection detection, preeclampsia risk assessment, maternal serum screening for Down syndrome, and karyotyping. Within the oncology sector, Sofiva Genomics delivers advanced cancer screenings, dynamic monitoring of tumor activity, and genetic evaluations for hereditary cancer predisposition. This includes specialized panels for women's cancers (breast, colon, ovarian, and endometrial), alongside human papillomavirus (HPV) screening. Furthermore, the company conducts genetic testing for rare diseases and provides specialized reproductive services such as preimplantation genetic diagnosis (PGD) and next-generation sequencing (NGS)-based preimplantation genetic screening (PGS). For newborns, their services encompass comprehensive "baby scans," screenings for hereditary sensorineural hearing loss, congenital central hypoventilation syndrome (CCHS), congenital cytomegalovirus (CMV) infection, and genetic risk assessment for atopic dermatitis. Beyond these specialized offerings, Sofiva Genomics also performs biochemical and chromosomal analyses, complemented by valuable advisory and support services for its clientele.
Share Price
$0.98617224
Last synced: 2026-11-10
Market Cap
$21.29M
Change (1 day)
-0.92%
Change (1 year)
-0.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sofiva Genomics Co.,Ltd. (6615)
Category
Healthcare
EPS for Sofiva Genomics Co.,Ltd. (6615)
EPS as of June 2026 TTM: $0.02
According to Sofiva Genomics Co.,Ltd.'s latest financial reports, its current EPS (TTM) is $0.02. At the end of 2025 the company had an EPS of $-0.01, a decrease compared to its 2024 EPS of $0.03.
EPS history for Sofiva Genomics Co.,Ltd. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.02 | -304.00% |
| 2025 | $-0.01 | -152.29% |
| 2024 | $0.03 | 48.86% |
| 2023 | $0.02 | -73.01% |
| 2022 | $0.07 | -32.57% |
| 2021 | $0.10 | 66.72% |
| 2020 | $0.06 | -41.41% |
| 2019 | $0.10 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $18.99 | 92,988.24% |
US
|
|
| $6.12 | 29,900.00% |
US
|
|
| $1.38 | 6,650.49% |
CN
|
|
| $14.83 | 72,596.08% |
US
|
|
| $5.09 | 24,850.98% |
US
|
Questions about Sofiva Genomics Co.,Ltd.'s earnings per share (EPS)
What is Sofiva Genomics Co.,Ltd.'s earnings per share (EPS)?
Sofiva Genomics Co.,Ltd.'s earnings per share (EPS) over the last twelve months is $0.02, as of Jun 2026.
What was Sofiva Genomics Co.,Ltd.'s earnings per share (EPS) in 2025?
In 2025, Sofiva Genomics Co.,Ltd.'s earnings per share (EPS) was $-0.01, compared with $0.03 in 2024.
How has Sofiva Genomics Co.,Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Sofiva Genomics Co.,Ltd.'s earnings per share (EPS) was highest in 2021 ($0.10) and lowest in 2025 ($-0.01).
How does Sofiva Genomics Co.,Ltd.'s earnings per share (EPS) compare with similar companies?
Sofiva Genomics Co.,Ltd.'s earnings per share (EPS) ($0.02) is lower than that of all 5 similar companies listed above. The highest among them is Thermo Fisher Scientific Inc., with $18.99.